The earnings miss may pressure the stock near-term, but positive clinical data and strong cash runway support the pipeline narrative. Watch for initiation of the Himalayas-1 Phase 3 trial in 1H 2026 and multiple data readouts in 2H 2026.
ORIC drugs
ORIC drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $9.57entry
- T+1 · 7mo ago 0.00%α −1.38% · $9.57
- T+5 · 6mo ago −6.06%α −8.04% · $8.99
- T+20 · 6mo ago −20.38%α −25.33% · $7.62
- T+60 · 4mo ago +21.63%α +18.89% · $11.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates of $0.31/share by 9.7%, as R&D spending increased to $31.4M. However, the company announced selection of rinzimetostat RP3D and positive clinical data, with cash of $419.7M funding operations into 2H 2028.
Key Financial Metrics
Key Facts
- Net loss per share $(0.34) vs consensus $(0.31) (EPS miss of ~9.7%)
- Q1 2026 net loss $35.8M vs $30.0M in Q1 2025, driven by higher R&D costs
- Cash, cash equivalents and investments $419.7M as of March 31, 2026
- R&D expenses $31.4M, up 27.5% YoY due to advancement of rinzimetostat and enozertinib
- Selected rinzimetostat 400 mg once daily as RP3D for Himalayas-1 Phase 3 trial in post-abiraterone mCRPC
- Positive rinzimetostat data showing landmark rPFS rates superior to standard of care
- Initiation of first Phase 3 registrational trial expected in 1H 2026
Financial Impact
EPS miss of $0.03 (9.7%) vs consensus; higher net loss due to increased R&D spending
Risk Factors
- EPS miss and higher net loss could disappoint short-term traders
- Clinical trial risks, including potential delays or negative data
- Dilution risk from continued ATM offerings (raised $59.9M in Q1 2026)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-203993 |
| Document: oric-20260504.htm | 0001193125-26-203993 |
| Document: 0001193125-26-203993-index-headers.html | 0001193125-26-203993 |
| Document: 0001193125-26-203993-index.html | 0001193125-26-203993 |
| Document: 0001193125-26-203993.txt | 0001193125-26-203993 |
| 8-K Data (Synthetic) | 0001193125-26-203993 |
Track record
12 reports on ORIC
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Press Release Neutral 5/10 Entry $7.52 Now $7.52 −0.00% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $7.59 Now $7.52 −0.92% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.72 Now $7.52 −2.59% settles Nov 23
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $8.91 Now $7.52 −15.60% settles Nov 17
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $13.17 to $9.24 Now $7.52 −42.90% ▼ −29.84% −29.28% vs SPY
- Oct 5, 20266w ago Press Release Bullish 6/10 Entry $11.98 to $11.31 Now $7.52 −37.23% ▼ −5.59% −5.45% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $12.49 to $11.81 Now $7.52 −39.79% ▼ −5.44% −5.87% vs SPY
- Aug 3, 202615w ago Press Release Neutral 5/10 Entry $13.47 to $13.73 Now $7.52 −44.17% ▲ +1.93% +2.03% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.91 to $10.16 Now $7.52 −15.60% ▲ +13.97% +12.96% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $7.82 to $8.63 Now $7.52 −3.84% ▲ +10.36% +9.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers